Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Authors
Keywords
-
Journal
Journal of Diabetes Investigation
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-11-21
DOI
10.1111/jdi.12980
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- A comparison of low volume ‘high-intensity-training’ and high volume traditional resistance training methods on muscular performance, body composition, and subjective assessments of training
- (2016) Jürgen Giessing et al. BIOLOGY OF SPORT
- Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
- (2016) Takamasa Ohki et al. CLINICAL DRUG INVESTIGATION
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies
- (2016) Akinori Hayashi et al. ENDOCRINE JOURNAL
- Body composition in overweight and obese women postpartum: bioimpedance methods validated by dual energy X-ray absorptiometry and doubly labeled water
- (2016) L Ellegård et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
- (2016) Kento Imajo et al. GASTROENTEROLOGY
- Non-alcoholic fatty liver disease and diabetes
- (2016) Jonathan M. Hazlehurst et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors in the treatment of type 2 diabetes
- (2014) Farhad M. Hasan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
- (2014) Masanori Yokono et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
- (2014) Atsuo Tahara et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- MR Imaging of Diffuse Liver Disease
- (2014) Thomas A. Hope et al. RADIOLOGIC CLINICS OF NORTH AMERICA
- The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study
- (2013) Emer M Guinan et al. Nutrition Journal
- Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
- (2013) Melania Gaggini et al. Nutrients
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
- (2012) G. Musso et al. DIABETOLOGIA
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Why Does NAFLD Predict Type 2 Diabetes?
- (2011) Guido Lattuada et al. Current Diabetes Reports
- A comparison of dual energy X-ray absorptiometry and bioelectrical impedance analysis to measure total and segmental body composition in healthy young adults
- (2011) Siobhan Leahy et al. EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2009) Amy G. Shah et al. Clinical Gastroenterology and Hepatology
- Quantification of hepatic steatosis with MRI: The effects of accurate fat spectral modeling
- (2009) Scott B. Reeder et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started